Precidex Injection is indicated for:
- Sedation of initially intubated and mechanically ventilated
- Patients during treatment in an intensive care setting.
- Sedation of non-intubated patients prior to and/or during surgical and other procedures.
Precidex (Dexmedetomidine Injection USP) is a FDA approved relatively selective alpha2 -adrenergic agonist. Dexmedetomidine has activity at a variety of locations throughout the central nervous system. The sedative and anxiolytic effects of dexmedetomidine result primarily from its activity in the locus ceruleus of the brain stem. Stimulation of alpha2-adrenergic receptors at this site reduces central sympathetic output, resulting in increased firing of inhibitory neurons. The presence of dexmedetomidine at alpha2-adrenergic receptors in the dorsal horn of the spinal cord modulates release of substance P and produces its analgesic effects. Dexmedetomidine hydrochloride is the S-enantiomer of medetomidine.